US 12,247,034 B1
Crystalline form of deuruxolitinib phosphate
Sean Wiedemann, Burlington, MA (US)
Assigned to Sun Pharmaceutical Industries, Inc., Princeton, NJ (US)
Filed by Sun Pharmaceutical Industries, Inc., Princeton, NJ (US)
Filed on May 10, 2024, as Appl. No. 18/661,225.
Claims priority of provisional application 63/636,516, filed on Apr. 19, 2024.
Int. Cl. A61K 31/519 (2006.01); C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) [A61K 31/519 (2013.01)] 14 Claims
 
1. A polymorph of a compound of Formula I:

OG Complex Work Unit Chemistry
wherein the polymorph is Form I; and
wherein Form I is characterized by a powder X-ray diffraction pattern comprising at least three peaks at angles (°2θ) selected from 4.03°±0.2°2θ, 14.54°±0.2°2θ, 24.95°±0.2°2θ, and 25.29°±0.2°2θ.
 
14. A pharmaceutical composition comprising the polymorph of claim 1 and a pharmaceutically acceptable carrier.